CA-XSOLLA
Shurick Agapitov, a visionary author and the Founder of Xsolla unveiled his groundbreaking new book, "Once Upon Tomorrow," today. This pioneering work offers a transformative and aspirational vision of the Metaverse, contrasting markedly with mainstream narratives. Agapitov's book is a thought-provoking journey into the possibilities and potential of the Metaverse, providing a unique perspective diverging from the views often presented at industry conferences and by technology CEOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130496363/en/
(Graphic: Business Wire)
"In 'Once Upon Tomorrow,' I present a vision of the Metaverse as a vast, inclusive, and transformative space. It's not just a digital frontier but a realm where creativity, innovation, and empowerment converge. This book is my invitation to creators, thinkers, and dreamers across the globe to join in shaping a future where technology amplifies human potential and fosters a world of limitless possibilities. The Metaverse, as I see it, is not about control or confinement but about unleashing the collective creativity and entrepreneurial spirit inherent in all of us," said Shurick Agapitov, Founder of Xsolla and acclaimed author of "Once Upon Tomorrow."
"Once Upon Tomorrow" delves into the untapped potential of the Metaverse, highlighting its capacity to unite emerging and legacy brands, create unforgettable consumer experiences, and enrich cultures globally. Agapitov emphasizes the Metaverse's role in democratizing opportunities and equal access to cutting-edge technologies. His vision extends beyond mere technological innovation, underscoring the Metaverse's potential to empower and reward content creators across the globe. The book also highlights the significant impact of the Metaverse on education, offering hope and opportunities for both children and adults worldwide. Agapitov advocates for a decentralized Metaverse moving away from Silicon Valley's dominance, placing control, profit potential, and freedom in the hands of creative communities.
"Once Upon Tomorrow" is more than just a book about the Metaverse; it's a roadmap to a future where technology serves humanity in all its diversity, fostering financial, social, and creative inclusivity. Agapitov envisions a future where every consumer-facing industry, from fashion to healthcare and entertainment, is transformed. The book also explores the potential impact of the Metaverse on business-to-business sectors, education, city planning, inter-government relations, and non-profit efforts.
Agapitov's insight into the evolution of technology, from the early days of Instagram and Snapchat to the future of immersive applications, is a key highlight of the book. He discusses the roles of various technology stakeholders, including internet hosting providers, website developers, cloud computing experts, infrastructure engineers, and the ongoing need for advanced networking and hardware. "Once Upon Tomorrow" is a visionary piece that invites readers to rethink the Metaverse and its limitless potential.
For additional information and to purchase please visit: onceupontomorrow.com
About Shurick Agapitov
As the founder of Xsolla, Inc., Shurick Agapitov is a highly respected innovator and advisor in gaming, Web3, Metaverse, and fintech. His trailblazing video game company integrates blockchain technology, providing developers with advanced tools and services for more effective game operations and sales. With a global presence, including offices in Los Angeles, Berlin, and Seoul, Xsolla, under Shurick’s leadership, is shaping the future of gaming and the Metaverse, fostering a more decentralized and inclusive industry.
For additional information about Shurick Agapitov please visit: themarque.com or LinkedIn.com
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130496363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom